Latest Content

Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.

A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.

Ronald Chin reflects on hospitality, setting boundaries and accepting his body, and how his greatest strengths and struggles both come from one open heart.

Joy Maulik, MSN, FNP-C, discusses why he built the MyUrova app and how men with prostate, bladder, kidney or testicular cancer can prepare for visits, understand their risk and set expectations for life after treatment.

Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.

Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution about spacing out immunotherapy doses.

Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.

Testicular cancer survivor Brian Sluga shares how faith, journaling and new goals, like training for marathons, helped him live a better life after cancer.

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.

Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.

Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.

Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.

Adding Imdelltra to Imfinzi maintenance helped people with extensive-stage small cell lung cancer live a median of 21.1 months vs. 12.7 months with Imfinzi alone in the phase 3 DeLLphi-305 trial.